ClearPoint Neuro, Inc. Q4 FY2024 earnings call

Key Statements

• Joe Burnett introduced the Fast. Forward phase, emphasizing extending lead in cell and gene therapy delivery, evolving the portfolio for fast/simple workflows, and expanding the global installed base.
• Danilo D'Alessandro detailed 2024 financials: revenue growth across segments, gross margin improvement, operating expenses, cash position, and an equity offering in March 2024 that strengthened the balance sheet.

Operational Highlights

• Launched new MR navigation and operating room systems, drug delivery technologies, and preclinical/clinical services.
• Added a new manufacturing facility, gained global regulatory clearances, built an IP portfolio, and expanded biopharma partner base to over 60 customers with 100+ activated centers worldwide.

ClearPoint Neuro's total revenues for the year ended December 31, 2024, were $31.4 million, a 31% increase from $24 million in 2023. Revenue is composed of three segments: 1. Biologics and drug delivery: Generated $17.3 million in 2024, a 27% increase from $13.6 million in 2023, driven by increased product sales as pharma partners advanced development programs. 2. Neurosurgery navigation: Reached $10.3 million in 2024, a 21% growth due to an expanded installed base and new product releases. 3. Capital equipment and software: Totaled $3.8 million in 2024, a 107% increase as the installed base expanded. For the fourth quarter of 2024, total revenues were $7.8 million, a 14% increase from $6.8 million in Q4 2023. Biologics and drug delivery revenue rose 4%, neurosurgery navigation revenue grew 43%, and capital equipment and software revenue saw a slight decrease. Gross margin for Q4 2024 was 61%, compared to 59% in Q4 2023.

ClearPoint Neuro expects 2025 revenue to be between $36 million and $41 million, representing 15%-31% growth. The range is driven by core medical device business growth, preclinical services scaling with GLP capabilities, and timing of preclinical facility expansion. Key initiatives include extending lead in biologics/drug delivery, evolving device portfolio for fast/simple procedures, and expanding global scale with 15-20 new site activations in 2025.

No specific risks detailed in the transcript, but general forward-looking statement risks mentioned, where actual results could differ materially from projections.

Q: Frank Takkinen asked about fast-tracked assets and revenue impact.

A: Expedited FDA processes could lead to drug approvals in the next two years, with potential $250 million+ in added revenue from 1% of affected patients.

Q: Mathew Blackman inquired about the 2025 guidance range.

A: The range is due to preclinical services timing uncertainty, core device business growth, and capital equipment lease agreements.

Q: Anderson Schock asked about new account activations.

A: Driven by hospital preparation for cell and gene therapy, laser therapy business, and operating room expansion, with a strong global funnel of interested customers.